Key Releases are ad hoc announcements pursuant to SIX Swiss Exchange Article 53 Listing Rules.
Header
News archive
News Archive Navigation
icon
News Archive Navigation Language
Language Preferences
Showing 1821 results
April 2019
-
In The NewsMedicines and transformative effectIn this Bloomberg interview, Vas Narasimhan, CEO of Novartis shares his thoughts on how medicines can have a transformative effect.
-
Media ReleaseSandoz resubmits biosimilar pegfilgrastim application to US FDASandoz pursues US approval for biosimilar pegfilgrastim, a long-acting version of supportive oncology medicine filgrastim Pegfilgrastim is used to reduce the incidence of neutropenia, one…
-
Featured NewsSustaining the momentum toward universal health coverage in Africa
The first pan-African Novartis Social Business stakeholder dialogue took place in Kampala, Uganda, on March 20, 2019.
-
Media ReleaseNovartis first-in-class Cosentyx® approved in China for psoriasis patientsChina Health Authority NMPA approved Cosentyx® (secukinumab) for moderate-to-severe plaque psoriasis in adult patients who are candidates for systemic therapy or phototherapy Cosentyx is…
-
Media ReleaseAveXis expands world-leading gene therapy manufacturing capacity with purchase of advanced biologics therapy manufacturing campus in Longmont, ColoradoFacility to become the largest of four state-of-the-art sites involved in manufacturing of AveXis gene therapies for pipeline of rare genetic diseases including spinal muscular atrophy …
-
Media ReleaseNovartis adds clinical and preclinical anti-inflammatory programs to portfolio with acquisition of IFM TreAcquisition will give Novartis one clinical and two preclinical programs targeting the NLRP3 inflammasome, a key component of the innate immune system Selective inhibition of the NLRP3…
March 2019
-
Key ReleaseNovartis receives FDA approval for Mayzent® (siponimod), the first oral drug to treat secondary progressive MS with active diseaseMayzent® (siponimod) is the first and only treatment specifically approved for patients with active secondary progressive multiple sclerosis (SPMS) in over 15 years[1] Up to 80% of patients…
-
What goes wrong with the window to the soul in glaucoma?
Speaking with Ganesh Prasanna, Director of Ophthalmology at NIBR.
-
Key ReleaseNovartis plans for Alcon spin-off on April 9, 2019Alcon obtained approval for listing on SIX Swiss Exchange and New York Stock Exchange Alcon will seek effectiveness of Form 20-F registration statement from the US Securities and Exchange…
-
Experimental gene therapy discovered in-house enters clinical testing
Novartis is taking its investigational gene therapy for a degenerative eye disease into clinical trials.
-
In The NewsIt's Time to "Pivot Towards Transformational Innovation"In this interview with Susie Gharib from Fortune, Vas Narasimhan, CEO of Novartis, shares his perspective on changing the culture within Novartis.
-
Visualizing immuno-oncology research
Learn how Novartis researchers are working to outsmart tumors.
Pagination
- ‹ Previous page
- 1
- …
- 73
- 74
- 75
- 76
- 77
- 78
- 79
- …
- 152
- › Next page